Caris Life Sciences, Inc. Common Stock Earnings Dividend

Caris Life Sciences, Inc. Common Stock’s revenue jumped 78.78% since last year same period to $216.17Mn in the Q1 2026. On a quarterly growth basis, Caris Life Sciences, Inc. Common Stock has generated -26.19% fall in its revenue since last 3-months.

Caris Life Sciences, Inc. Common Stock’s net profit jumped 99.5% since last year same period to $-0.51Mn in the Q1 2026. On a quarterly growth basis, Caris Life Sciences, Inc. Common Stock has generated -100.62% fall in its net profits since last 3-months.

Caris Life Sciences, Inc. Common Stock’s net profit margin jumped 99.72% since last year same period to -0.24% in the Q1 2026. On a quarterly growth basis, Caris Life Sciences, Inc. Common Stock has generated -100.84% fall in its net profit margins since last 3-months.

Caris Life Sciences, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.02 - a -268% fall from last quarter’s estimates.

Caris Life Sciences, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.02.

Caris Life Sciences, Inc. Common Stock’s earning per share (EPS) jumped 99.49% since last year same period to -0 in the Q1 2026. This indicates that the Caris Life Sciences, Inc. Common Stock has generated 99.49% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Caris Life Sciences, Inc. Common Stock’s return on assets (ROA) stands at 0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Caris Life Sciences, Inc. Common Stock’s return on equity (ROE) stands at 0.28.